Science Explorer Back to mapMap

Most cited papers from Erasmus MC Cancer Institute

What are the most cited papers from Erasmus MC Cancer Institute?

The most cited paper from Erasmus MC Cancer Institute is "Signatures of mutational processes in human cancer" (Australian Pancreatic Cancer Genome Initiative et al., 2013), with 10,284 citations. Next come "Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer" (8,632) and "Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer" (5,583).

Showing 50 of 60 papers. Every paper with more than 790 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Signatures of mutational processes in human cancer Australian Pancreatic Cancer Genome Initiative et al. · Nature Open access 14 Aug 2013 10,284
2 Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer Julie Renee Brahmer et al. · New England Journal of Medicine Open access 31 May 2015 8,632
3 Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer Pieter van Hagen et al. · New England Journal of Medicine Open access 31 May 2012 5,583
4 Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches Joshua A Welsh et al. · Journal of Extracellular Vesicles Open access Feb 2024 4,377
5 Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Stephen G. O’Brien et al. · New England Journal of Medicine Open access 12 Mar 2003 3,593
6 Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma Joaquim Bellmunt, Ronald de Wit, David J. Vaughn et al. · New England Journal of Medicine Open access 17 Feb 2017 3,457
7 Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN Hartmut Döhner et al. · Blood Open access 7 Jul 2022 3,286
8 Patterns of somatic mutation in human cancer genomes Christopher D. Greenman et al. · Nature Open access Mar 2007 3,167
9 Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers Karoline B. Kuchenbaecker et al. · JAMA Open access 20 Jun 2017 2,963
10 EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent Nicolas Mottet et al. · European Urology Open access 7 Nov 2020 2,876
11 International network of cancer genome projects Jennifer L. Jennings et al. · Nature Open access256 authors 13 Apr 2010 2,439
12 Landscape of somatic mutations in 560 breast cancer whole-genome sequences Serena Nik‐Zainal et al. · Nature Open access 29 Apr 2016 2,395
13 Genome-wide association study identifies novel breast cancer susceptibility loci Douglas F. Easton et al. · Nature Open access239 authors 27 May 2007 2,342
14 DNA Damage, Aging, and Cancer Jan H.J. Hoeijmakers · New England Journal of Medicine Open access 7 Oct 2009 2,241
15 EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood Michael Weller et al. · Nature Reviews Clinical Oncology ReviewOpen access 8 Dec 2020 2,063
16 ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma Nicole Concin et al. · International Journal of Gynecological Cancer Open access 23 Dec 2020 2,012
17 Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition Mieke Kriege, Cecile T.M. Brekelmans, Carla Boetes et al. · New England Journal of Medicine Open access 28 Jul 2004 1,690
18 Cremophor EL Hans A. J. Gelderblom, Jaap Verweij, Kees Nooter et al. · European Journal of Cancer Sep 2001 1,658
19 Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up Paolo Giovanni Casali et al. · Annals of Oncology Open access 28 Mar 2018 1,636
20 Association analysis identifies 65 new breast cancer risk loci Kyriaki Michailidou et al. · Nature Open access362 authors 20 Oct 2017 1,602
21 Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity Ursula Fünfschilling, Lotti M. Supplie, Don Mahad et al. · Nature Open access 27 Apr 2012 1,571
22 First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study Arjun Vasant Balar, Daniel Castellano, Peter H. O’Donnell et al. · The Lancet Oncology 26 Sep 2017 1,356
23 A Genetic Screen Implicates miRNA-372 and miRNA-373 As Oncogenes in Testicular Germ Cell Tumors Pieter Mathijs Voorhoeve, Carlos le Sage, Mariëtte Schrier et al. · Cell Open access Mar 2006 1,270
24 Lamina-Associated Domains: Links with Chromosome Architecture, Heterochromatin, and Gene Repression Bas van Steensel, Andrew S. Belmont · Cell Open access May 2017 1,258
25 EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent Philip A Cornford et al. · European Urology Open access 13 Apr 2024 1,253
26 First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial Paul Baas et al. · The Lancet Open access 2021 1,226
27 Heating the patient: a promising approach? Jacoba van der Zee · Annals of Oncology Open access Aug 2002 1,224
28 Pan-cancer whole-genome analyses of metastatic solid tumours Peter Priestley et al. · Nature Open access 23 Oct 2019 1,222
29 Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group Fernanda Mosele et al. · Annals of Oncology Open access 24 Aug 2020 1,221
30 Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes Nasim Mavaddat et al. · The American Journal of Human Genetics Open access269 authors 13 Dec 2018 1,213
31 Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial Ian Robert Judson, Jaap Verweij, Hans A. J. Gelderblom et al. · The Lancet Oncology Open access 5 Mar 2014 1,195
32 Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions Patrick Yung Wen et al. · Neuro-Oncology Open access 20 Apr 2020 1,183
33 HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures Helen Ruth Davies et al. · Nature Medicine Open access 13 Mar 2017 1,158
34 Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial Remi A. Nout, VTHBM Smit, Hein Putter et al. · The Lancet Mar 2010 1,154
35 EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer Philip A Cornford et al. · European Urology Open access 8 Oct 2020 1,142
36 National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Catharine M. Sturgeon et al. · Clinical Chemistry 28 Nov 2008 1,141
37 European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas Michael Weller et al. · The Lancet Oncology Open access 5 May 2017 1,122
38 Large-scale genotyping identifies 41 new loci associated with breast cancer risk Kyriaki Michailidou et al. · Nature Genetics Open access222 authors 27 Mar 2013 1,109
39 Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial Eva Versteijne et al. · Journal of Clinical Oncology Open access 27 Feb 2020 1,101
40 Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ Alessandro Gronchi et al. · Annals of Oncology Open access 22 Jul 2021 1,057
41 Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial Roger Stupp et al. · The Lancet Oncology Open access 19 Aug 2014 1,053
42 Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms Guido Rindi, Özgür Mete, Silvia Uccella et al. · Endocrine Pathology Open access Mar 2022 1,029
43 Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer Jürgen Wolf et al. · New England Journal of Medicine Open access 2 Sep 2020 1,029
44 Lomustine and Bevacizumab in Progressive Glioblastoma Wolfgang Wick et al. · New England Journal of Medicine Open access 15 Nov 2017 1,008
45 Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study Philippe Moreau et al. · The Lancet Open access 3 Jun 2019 973
46 Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group Pieter Sonneveld et al. · Blood Open access 22 Mar 2016 945
47 Summary of the Recommendations on Sexual Dysfunctions in Men Francesco Montorsi et al. · The Journal of Sexual Medicine 29 Oct 2010 944
48 Testicular germ-cell tumours in a broader perspective J. Wolter Oosterhuis, Leendert H. J. Looijenga · Nature reviews. Cancer Review Mar 2005 932
49 Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Philippe Moreau, Jesús F. San Miguel, Pieter Sonneveld et al. · Annals of Oncology Open access 6 Apr 2017 882
50 Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer Mansoor Raza Mirza et al. · New England Journal of Medicine Open access 27 Mar 2023 865

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.